LBBAP and Bicameral Leadless Pacemaker Procedures – 2025 Overview
Published by Artificial Intelligence Doctor • ABC Farma – Clinical AI Insights
Question 1:
How many pacemaker procedures in 2025 in America of LBBAP and Bicameral LP?
Answer:
There isn’t a single public U.S. registry that breaks out 2025 procedure counts by technique, so no authoritative “official” totals exist yet.
Dual-chamber leadless pacemakers (bicameral LP, Abbott AVEIR™ DR):
Abbott’s 2025 Product Performance Report lists Registered U.S. implants of its AVEIR DR models as
4 199 (LSP202V) and 4 662 (LSP201A) — ≈ 8 861 cumulative U.S. implants.
These are cumulative figures through the 2025 data cut, not “2025-only.”
AMA created Category III CPT codes 0795T–0804T and CMS added HCPCS C1605 (device pass-through) in mid-2024, allowing claims-based tracking—national totals not yet released.
Left Bundle Branch Area Pacing (LBBAP):
No dedicated CPT code exists; conduction-system pacing uses standard pacemaker codes.
Therefore, no verified 2025 national count is available.
About 300 000 cardiac implantable devices are placed annually in the U.S., and LBBAP adoption is growing rapidly in centers and trials.
For market estimation, combine Abbott registry data, hospital logs, and claim codes (0795T–0804T + C1605), recognizing that LBBAP volumes cannot yet be isolated until a new CPT code is established.
Question 2:
Is this true: LBBAP Procedures in 2025 — Leadless LBBAP is a brand-new technique introduced in 2025 using Abbott’s investigational Aveir Conduction System Pacing (CSP) device. Only 10 patients underwent leadless LBBAP procedures in the U.S. as part of first-in-human trials. These procedures were part of early feasibility studies and are not yet widely adopted in clinical practice.
Answer:
Almost—but not exactly.
“Brand-new in 2025?”
The first leadless LBBAP procedures using Abbott’s investigational AVEIR Conduction System Pacing (CSP) were announced December 17 2024 (first-in-human) and expanded with data at HRS 2025.
Thus the technique emerged at the end of 2024 and gained traction in 2025.
“Only 10 patients in the U.S.?”
The “10” figure refers to successful implants in the first-in-human feasibility cohort (14 enrolled; 2 deferred; 2 aborted → 10 successful).
Those were not U.S.-only; the first implants were performed in Prague, Czech Republic.
Therefore, “10 patients in the U.S.” is incorrect.
“Early feasibility and not yet widely adopted?”
Correct — Abbott classified this as an acute clinical feasibility study, meaning it remains investigational and not routine practice.
Bottom line: The technique is new (2024–2025) and still investigational; the “10 U.S. patients” claim is inaccurate since the early implants were mostly non-U.S.